Urothelial carcinoma

Researchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…

This phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some b…

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…

This study tests an experimental daily pill called zanzalintinib in 44 adults with advanced bladder cancer that has continued to grow after previous treatments. The goal is to see if the drug can shrink tumors or slow the cancer's progression. Participants will take the pill once…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This phase II trial tests an experimental drug called TR115 in people with advanced solid tumors that have a mutation in the ARID1A gene. The study includes patients with platinum-resistant ovarian clear cell carcinoma, endometrial cancer that failed immunotherapy, and other tumo…

This trial tests whether adding an oral drug called capivasertib to standard immunotherapy can help people with advanced bladder cancer whose tumors have stopped responding to immunotherapy alone. Capivasertib is already approved for breast cancer, and earlier research hints it m…

This early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…

This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with two rare types of cancer: papillary renal carcinoma and less common forms of bladder cancer. The drug is given by IV every two weeks for up to three years. The main goal is to see how many…

This phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less seve…

This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-stage trial tests a procedure called calcium electroporation for bladder tumors. Doctors inject calcium into the tumor and then apply short electric pulses to destroy cancer cells. The study will include 20 patients who cannot have standard surgery or other treatments.…

This phase 3 study tests a new drug called SYS6002 against standard chemotherapy in 406 people with advanced bladder cancer (urothelial carcinoma) that has worsened after platinum chemo and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is n…

This study tests whether the drug avelumab can help keep metastatic urothelial carcinoma (a type of bladder cancer) from growing after patients have already received two lines of chemotherapy. About 144 adults whose cancer has not worsened after second-line chemo will receive ave…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This Phase 2 trial compares a new drug called SYS6002 to the current standard treatment PADCEV in 100 people with advanced bladder cancer that has worsened after chemotherapy and immunotherapy. The study is not yet recruiting and will check for side effects and how well the drugs…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study looks at whether a supportive product called Neuridase can help reduce nerve damage (peripheral neuropathy) caused by a combination of two cancer drugs (enfortumab vedotin and pembrolizumab) in people with advanced bladder cancer. About 40 participants will receive sta…

This study looks at whether giving standard bladder cancer drugs in the morning or afternoon changes how well they work and how many side effects they cause. About 224 adults with advanced bladder cancer will be randomly assigned to receive their treatment either before 11:30 a.m…

Researchers at M.D. Anderson Cancer Center are building a large collection of biological samples and clinical data from people with urothelial carcinoma, a common type of bladder cancer, and related urinary tract cancers. The study will enroll up to 50,000 adults with known or su…

This study examines two microscopic details in bladder cancer tumors—how deep early cancer cells have invaded and whether small clusters of cells are present at the tumor's edge. Researchers will look at tissue samples from 100 patients to see if these features can predict if the…

This study examines stored tumor samples from 100 bladder cancer patients who had their bladder removed. Researchers will measure the amount of supportive tissue, immune cells, and immune clusters near the tumor. The goal is to see if these features are linked to how long patient…

This study looks back at how well a combination of two drugs—enfortumab vedotin and pembrolizumab—works as the first treatment for people with advanced bladder cancer that has spread. Researchers will collect data from 361 patients around the world to see how long they live and h…